Gilead Sciences
1993
| Case No.
E9
Case involves an early stage biotechnology company raising its fourth round of money in a very capital intensive field. Should the company do a late stage private equity financing and try to meet its product development goals or take the risk of filing an initial public offering before the key product development and regulatory milestones have been met?
This material is available for download by current Stanford GSB students, faculty, and staff, as well as Stanford GSB alumni. For inquires, contact the
Case Writing Office.
Download
Available for Purchase